Evidence map›Paper›PMID 31763513›Full record

ArticleKidney cancer (Clifton, Va.)2019

miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma.

Xue Gong, Hongjuan Zhao, Matthias Saar, Donna M Peehl, James D Brooks

Open access · diamondAbstract read
In one paragraph

Article in Kidney cancer (Clifton, Va.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. MicroRNA Signature in Renal Cell Carcinoma.Frontiers in oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Xue GongDepartment of Urology, School of Medicine, Stanford University, Stanford, California, USA.
Hongjuan ZhaoDepartment of Urology, School of Medicine, Stanford University, Stanford, California, USA.
Matthias SaarDepartment of Urology and Pediatric Urology, University of Saarland, Homburg/Saar, Germany.
Donna M PeehlDepartment of Urology, School of Medicine, Stanford University, Stanford, California, USA.
James D BrooksDepartment of Urology, School of Medicine, Stanford University, Stanford, California, USA.
Stanford University · USSaarland University · DEUniversity of California, San Francisco · US

Funding

New Tools for Prostate Cancer Detection and PrognosticationU01CA152737 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D., GAMBHIR, SANJIV S · 2010 to 2015
$2.8M
NCI NIH HHS U01 CA152737
6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is molecularly diverse and distinct molecular subtypes show different clinical outcomes. MicroRNAs (miRNAs) are essential components of gene regulatory networks and play a crucial role in progression of many cancer types including ccRCC.

objectiveIdentify prognostic miRNAs and determine the role of miR-22 in ccRCC.

methodsHierarchical clustering was done in R using gene expression profiles of over 450 ccRCC cases in The Cancer Genome Atlas (TCGA). Kaplan-Meier analysis was performed to identify prognostic miRNAs in the TCGA dataset. RNA-Seq was performed to identify miR-22 target genes in primary ccRCC cells and Matrigel invasion assay was performed to assess the effects of miR-22 overexpression on cell invasion.

resultsHierarchical clustering analysis using 2,621 prognostic genes previously identified by our group demonstrated that ccRCC patients with longer overall survival expressed lower levels of genes promoting proliferation or immune responses, while better maintaining gene expression associated with cortical differentiation and cell adhesion. Targets of 26 miRNAs were significantly enriched in the 2,621 prognostic genes and these miRNAs were prognostic by themselves. MiR-22 was associated with poor overall survival in the TCGA dataset. Overexpression of miR-22 promoted invasion of primary ccRCC cells

conclusionsOur results suggest that ccRCCs with differential clinical outcomes have distinct transcriptomes for which miRNAs could serve as master regulators. MiR-22, as a master regulator, promotes ccRCC progression at least in part by enhancing cell invasion.

Indexed as

clear cell renal cell carcinomaMicroRNAmiR-22survivalTCGA

Identifiers

PMID31763513
PMCPMC6839454
OpenAlexW2944753076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.